MBX Biosciences' Phase 3 hypoparathyroidism trial enrolls, obesity pipeline advancesNov 16Clinical readoutcanvuparatideMBX BiosciencesUpdated
Altimmune reports Q3 2026 results as pemvidutide programs advance in MASH and AUDNov 12Quarterly updateAltimmune, Inc.MetaVia Inc.
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
MetaVia reports Q2 2026 results, all patients reach top DA-1726 dosesAug 6Quarterly updateMetaVia Inc.
MetaVia completes dose titration in Phase 1 obesity trial of DA-1726Jul 9Clinical readoutMetaVia Inc.